These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. WHO expectation and industry goals. Vandersmissen W Vaccine; 2001 Feb; 19(13-14):1611-5. PubMed ID: 11166883 [TBL] [Abstract][Full Text] [Related]
4. Global vaccine project gets a shot in the arm. Check E Nature; 2005 Jan; 433(7024):345. PubMed ID: 15674258 [No Abstract] [Full Text] [Related]
5. The global vaccine enterprise: a developing world perspective. Shin SI Nat Med; 1998 May; 4(5 Suppl):503-5. PubMed ID: 9585198 [No Abstract] [Full Text] [Related]
6. Key drivers behind the development of global vaccine market. Gréco M Vaccine; 2001 Feb; 19(13-14):1606-10. PubMed ID: 11166882 [No Abstract] [Full Text] [Related]
7. Vaccine Assistance To Low- And Middle-Income Countries Increased To $3.6 Billion In 2014. Haakenstad A; Birger M; Singh L; Liu P; Lim S; Ng M; Dieleman JL Health Aff (Millwood); 2016 Feb; 35(2):242-9. PubMed ID: 26858376 [TBL] [Abstract][Full Text] [Related]
8. Modern vaccines. Progress towards vaccines we need and do not have. Robbins A Lancet; 1990 Jun; 335(8703):1436-8. PubMed ID: 1972216 [No Abstract] [Full Text] [Related]
9. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Clemens J; Jodar L Nat Med; 2005 Apr; 11(4 Suppl):S12-5. PubMed ID: 15812482 [TBL] [Abstract][Full Text] [Related]
11. Drive to vaccinate children in developing countries faces "acute crisis" because of high costs. Moszynski P BMJ; 2010 May; 340():c2576. PubMed ID: 20462931 [No Abstract] [Full Text] [Related]
12. Vaccines as a global imperative--a business perspective. Stéphenne J Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955 [TBL] [Abstract][Full Text] [Related]
15. Win-win interactions between the public and private sectors. Batson A Nat Med; 1998 May; 4(5 Suppl):487-91. PubMed ID: 9585192 [No Abstract] [Full Text] [Related]
16. Desirable attributes of vaccines for deployment in low-resource settings. Chen D; Zehrung D J Pharm Sci; 2013 Jan; 102(1):29-33. PubMed ID: 23136115 [TBL] [Abstract][Full Text] [Related]
17. A real shot. Diamond B Nat Med; 2005 Apr; 11(4 Suppl):S3-4. PubMed ID: 15812487 [No Abstract] [Full Text] [Related]
18. What are the economic barriers of antibiotic R&D and how can we overcome them? Renwick M; Mossialos E Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625 [No Abstract] [Full Text] [Related]
19. Costs of vaccine programs across 94 low- and middle-income countries. Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184 [TBL] [Abstract][Full Text] [Related]
20. Medicine. The intangible value of vaccination. Rappuoli R; Miller HI; Falkow S Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712 [No Abstract] [Full Text] [Related] [Next] [New Search]